Stocktoria
CORCEPT THERAPEUTICS INC CORT
CORCEPT THERAPEUTICS INC financials (annual)
Bars are annual figures from 2016 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $761.4M | $675.0M | $482.4M | $401.9M | $366.0M | $353.9M | $306.5M | $251.2M | $159.2M | $81.3M |
| R&D expense | $254.9M | $246.9M | $184.4M | $131.0M | $113.9M | $114.8M | $89.0M | $75.2M | $40.4M | $23.8M |
| SG&A expense | $448.7M | $280.3M | $184.3M | $152.8M | $122.4M | $105.3M | $100.4M | $81.3M | $62.4M | $45.2M |
| Operating income | $44.8M | $137.0M | $107.3M | $112.6M | $124.5M | $128.2M | $111.6M | $89.5M | $52.9M | $10.2M |
| Income tax | -$33.2M | $20.3M | $18.4M | $14.8M | $12.5M | $25.6M | $22.5M | $16.7M | -$76.3M | $0 |
| Net income | $99.7M | $141.2M | $106.1M | $101.4M | $112.5M | $106.0M | $94.2M | $75.4M | $129.1M | $8.1M |
| EPS (diluted) | $0.82 | $1.23 | $0.94 | $0.87 | $0.89 | $0.85 | $0.77 | $0.60 | $1.04 | $0.07 |
| Operating cash flow | $142.0M | $198.3M | $126.7M | $120.3M | $167.9M | $152.0M | $136.1M | $115.7M | $60.9M | $18.4M |
| Free cash flow | $141.8M | $196.1M | $126.5M | $119.9M | $167.4M | $150.7M | $135.0M | $115.4M | $60.5M | $18.2M |
| Cash & equivalents | $120.5M | $127.7M | $135.6M | $66.3M | $77.6M | $76.2M | $31.3M | $41.6M | $31.1M | $51.5M |
| Inventory | $12.9M | $12.4M | $7.7M | $6.1M | $5.0M | $4.9M | $5.4M | $4.7M | $4.6M | $2.3M |
| Total assets | $836.7M | $840.6M | $621.5M | $583.4M | $423.8M | $571.7M | $412.3M | $311.7M | $220.5M | $68.8M |
| Total liabilities | $188.8M | $161.0M | $114.8M | $81.6M | $48.0M | $48.4M | $41.1M | $35.8M | $29.6M | — |
| Shareholders' equity | $647.8M | $679.6M | $506.7M | $501.8M | $375.8M | $523.3M | $371.2M | $275.9M | $191.0M | $41.4M |
Growth · year-over-year · Revenue CAGR 28.2%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth | +12.8% | +39.9% | +20.0% | +9.8% | +3.4% | +15.5% | +22.0% | +57.8% | +95.8% | — |
| Net income growth | -29.4% | +33.0% | +4.7% | -9.9% | +6.1% | +12.6% | +24.9% | -41.6% | +1486.3% | — |
| EPS growth | -33.3% | +30.9% | +8.0% | -2.2% | +4.7% | +10.4% | +28.3% | -42.3% | +1385.7% | — |
| Free cash flow growth | -27.7% | +55.0% | +5.5% | -28.4% | +11.1% | +11.6% | +17.0% | +90.6% | +232.6% | +484.5% |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.